Synapse Analytical Labs LLC

Synapse Analytical Labs LLC was paid $2.16M by Medicaid between Jan 2018 and Nov 2022, across 34 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 70% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#34 of 128

Median peer was paid$268K

This provider vs. median8.1×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	7,310	$1.25M
2019	2,199	$268K
2020	5,818	$438K
2021	10,225	$90K
2022	12,111	$112K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	70%	9,413	3,457	$1.52M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	11%	2,255	1,638	$245K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	5.6%	345	333	$121K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.9%	1,055	881	$84K
87481		1.3%	1,996	1,492	$29K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	484	374	$18K
87541		<1%	1,354	1,004	$13K
87486		<1%	1,163	898	$13K
87581		<1%	1,356	1,006	$13K
87640		<1%	1,687	1,295	$13K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,710	1,289	$10K
87653		<1%	1,991	1,489	$10K

22 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,520	$10K
87500		<1%	1,909	$10K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,412	$10K
87641		<1%	1,904	$10K
87556		<1%	884	$8K
87561		<1%	928	$8K
87631		<1%	975	$7K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	546	$7K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	279	$5K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	59	$2K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	707	$845.31
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	176	$642.96
87506		<1%	23	$589.49
87529		<1%	358	$426.19
87150		<1%	55	$225.24
87496		<1%	221	$155.38
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	240	$116.39
87563		<1%	467	$83.49
87498		<1%	56	$44.40
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	74	$19.77
87186		<1%	48	$4.63
87511		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLAWTON, PATRICK (CFO)

Same official

Other billing entities under LAWTON, PATRICK

Full network →

Provider	Location	Paid
Firstox Laboratories, LLC	Irving, TX	$1.34M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.